Please assess the completion status of the following clinical trial:

Trial Title: A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Average to Very Serious Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria (Healthy Patients):~* Males and females, ages 18 to 55 years, inclusive, at screening~* Healthy subjects, as determined by no clinically significant deviations from normal in medical history, physical examination, 12-lead ECGs, vital signs, and clinical laboratory results~* Body mass index (BMI) of 18.0 to 30.0 kg/m2, inclusive, at screening~* Body weight between 55 kg and 105 kg, inclusive, at screening~* Women must not be breastfeeding~Exclusion Criteria (Healthy Patients):~* Previous participation in the current study~* Participation in a drug study or exposure to any investigational drug or placebo within 2 months prior to (the first) drug administration in the current study~* Employees of PRA or the Sponsor and their relatives~* Any significant acute or chronic medical condition that presents a potential risk to the subject and/or that may compromise the objectives of the study, including active, or history of, liver disease, or intestinal disorder including irritable bowel syndrome~* Current or recent (within 3 months of study treatment administration) gastrointestinal disease that could affect pharmacokinetics; history of cholecystectomy is not allowed~Inclusion Criteria (Psoriasis Patients):~* Males and females, ages 18 to 70 years, inclusive, at screening~* BMI of 18.0 to 35.0 kg/m2, inclusive, at screening~* Body weight between 55 kg and 120 kg, inclusive, at screening~* Diagnosed with stable chronic plaque psoriasis, for at least 6 months prior to screening and be candidates for either photo-therapy or systemic treatment~* Moderate-to-severe intensity of psoriasis as defined by:~  1. Affected body surface area (BSA) of ≥10%~ 2. Psoriasis Area and Severity Index (PASI) ≥12~ 3. Physician Global Assessment (PGA; 6-point scale) ≥3~Exclusion Criteria (Psoriasis Patients):~* Previous participation in the current study~* Participation in a drug study or exposure to any investigational drug or placebo within 2 months prior to (the first) drug administration in the current study~* Employees of PRA or the Sponsor and their relatives~* Any significant acute or chronic medical condition that presents a potential risk to the subject and/or that may compromise the objectives of the study, including active, or history of, liver disease, or intestinal disorder including irritable bowel syndrome~* Current or recent (within 3 months of study treatment administration) gastrointestinal disease that could affect pharmacokinetics; history of cholecystectomy is not allowed~Other protocol defined inclusion/exclusion criteria could apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Part A Single Ascending Dose (SAD) in Healthy Patients (Type: EXPERIMENTAL): Healthy patient will receive single escalating oral doses of BMS-986251 or placebo
- Part B Multiple Ascending Dose (MAD) in Healthy Patients (Type: EXPERIMENTAL): Healthy patients will receive daily escalating oral doses of BMS-986251 or placebo
- Part C Multiple Dosing in Psoriasis Patients (Type: EXPERIMENTAL): Psoriasis patients will receive daily escalating oral doses of BMS-986251 or placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues